11 November 2026
("EDX Medical" or the "Group" or "Company")
Appointment of Directors
CAMBRIDGE, UK: EDX Medical Group plc, which develops and supplies innovative digital diagnostic products and services to improve the early detection and treatment of major diseases, announces the Company has appointed Dr Joanne Hackett and Mr Peter Collins as non-executive directors.
Dr Hackett and Mr Collins, who have been appointed with immediate effect, are highly experienced in the strategic planning and commercialisation of diagnostic and health care solutions.
Dr Hackett has global experience across academic, business and clinical institutions. She is Vice President and Global Head of Health System Services for IQVIA, a leading provider of clinical research services and commercial insights to the life sciences and healthcare industries. Previous appointments include chief commercial officer, Genomics England, chief commercial officer and interim CEO, Precision Medicine Catapult, Director of Commercial Development, UCL Partners and Strategy Lead, Pfizer Neusentis.
Mr Collins is a precision oncology and molecular diagnostics executive with a track record of identifying, building and commercialising breakthrough technologies across companion diagnostics, liquid biopsy, and molecular residual disease before widespread market adoption. He has held senior leadership roles at DxS, GSK, Guardant Health, Inivata, and SAGA Diagnostics, translating scientific innovation into clinically adopted, reimbursed and scalable products through business development, commercial strategy, market access, strategic partnerships and company building.
Dr Mike Owen, chairman of EDX Medical, commented: “We are delighted to welcome two outstanding industry figures in Joanne and Peter to the Board. They bring a wealth of experience which will serve the Company well.”
Professor Sir Chris Evans, founder and chief scientific officer, EDX Medical, commented: “Joanne and Peter are exceptional talents and their skills, particularly in the commercialising of companies will be a huge asset as we continue to build EDX Medical.”
Additional information
Dr Hackett aged 47 holds no ordinary shares in the Company.
Dr Hackett holds or has held the following directorships and/or partnerships in the past five years:
Current
IZY Capital Partners Limited
Reset Health Limited
Past
eLife Sciences Publications Limited
AgeX Therapeutics Inc
Seaport Topco Limited
Peter Collins aged 67 holds no ordinary shares in the Company.
Peter Collins has held the following directorships and/or partnerships in the past five years:
CellBxHealth plc
Saga Diagnostics UK Limited
Collins Biotech Consulting SRL
There is no further information required to be disclosed under Schedule Two, paragraph (g) of the AIM Rules for Companies.
Contacts
Canaccord Genuity Limited (Nominated Adviser and Broker) | |
Stuart Andrews | +44 (0) 20 7523 8318 |
Media House International | |
Ramsay Smith Gary McQueen | +44 (0)7788 414856 + 44 (0)7834 694609 |
IFC Advisory (Investor Relations) | |
Graham Herring Tim Metcalfe | +44 (0) 203 934 6630 |
About EDX Medical Group plc
The EDX Medical Group plc is listed on the AIM market (TIDM: EDX).
EDX Medical was founded by Professor Sir Christopher Evans, OBE, a medical and life sciences entrepreneur with more than 30 years of experience, together with CEO, Dr Mike Hudson.
By translating clinical insights into pragmatic solutions combining advanced biological and digital technologies, EDX Medical seeks to cost effectively improve the detection and characterisation of disease to personalise treatment in a timely fashion. Early disease detection and biologically based personal treatment optimisation is considered to be the most impactful way of improving patient outcomes, reducing deaths and lowering the cost of healthcare globally.
EDX Medical Group provides doctors, hospitals and insurers/payers with access to a portfolio of the best clinical diagnostics products and services. The Company operates its own facilities in Cambridge, UK, and has strategic product and technology partnerships with organisations such as Thermo Fisher EMEA Ltd, a world leader in supplying life sciences solutions and services.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.